Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Plos One|June 23, 2012
Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune responseBarbara Morandi, Lorenzo Mortara, Laura Chiossone, et al.
Frontiers in Immunology|November 22, 2019
Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor GeneFrancesco Acquati, Lorenzo Mortara, Annarosaria De Vito, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2019
Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategiesDenisa Baci, Antonino Bruno, Caterina Cascini, et al.
Vaccines|December 28, 2021
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and AngiogenesisMaria Teresa Palano, Matteo Gallazzi, Martina Cucchiara, et al.
Virology Journal|September 2, 2006
SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251Pascale Villefroy, Franck Letourneur, Zoe Coutsinos, et al.
Frontiers in Immunology|January 31, 2022
When a Friend Becomes Your Enemy: Natural Killer Cells in Atherosclerosis and Atherosclerosis-Associated Risk FactorsMaria Teresa Palano, Martina Cucchiara, Matteo Gallazzi, et al.
Endocrine|September 30, 2022
A potential role of human RNASET2 overexpression in the pathogenesis of Graves' diseaseDaniela Gallo, Annarosaria De Vito, Rossella Roncoroni, et al.
Cancers|March 22, 2020
Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and RejectionAnnarosaria De Vito, Paola Orecchia, Enrica Balza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic originEnrica Balza, Lorenzo Mortara, Francesca Sassi, et al.
International Journal of Endocrinology|December 23, 2015
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid CancerEleonora Monti, Michela Bovero, Lorenzo Mortara, et al.
Pageof 9